Key facts
- This page summarizes Stephen Wargacki's Form 4 filing for Aquestive Therapeutics, Inc. (AQST).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 11 Mar 2024, 10:34.
Stephen Wargacki - 10 Mar 2023 Form 4 Insider Report for Aquestive Therapeutics, Inc. (AQST)
- Reporting relationship
- SVP, Research & Development
- Issuer ticker
- AQST
- Reported as of
- 10 Mar 2023
- Net transaction value
- -$1,572
- SEC form
- 4
- Accepted by SEC
- 11 Mar 2024, 10:34:53 UTC
- Prior SEC filing
- 09 Mar 2023
- Next SEC filing
- 05 May 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Lori Braender, as Attorney-In-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Stephen Wargacki filed Form 4 for Aquestive Therapeutics, Inc. (AQST) on 11 Mar 2024.
Change
- Previous filing in this sequence was filed on 09 Mar 2023.
- Current net transaction value: -$1,572.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AQST
transaction
Common Stock
Tax liability
- Transaction value
- $1,572
- Shares
- -1,981
- Change %
- -1.2%
- Price
- $0.7937
- Shares after
- 158,419
- Date
- 10 Mar 2023
- Ownership
- Direct
- Footnotes
- F1, F2
AQST
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +112,500
- Change %
- +71%
- Price
- $0.000000
- Shares after
- 270,919
- Date
- 07 Mar 2024
- Ownership
- Direct
- Footnotes
- F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AQST
transaction
Derivative
Non-Qualified Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +56,250
- Change %
- Price
- $0.000000
- Shares after
- 56,250
- Date
- 07 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 56,250
- Exercise price
- $5.68
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person.
Footnote F2
The original Form 3, filed on 1/1/23, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported the inclusion of shares vested that occurred on 3/10/22 as a total of 4,663 shares vested and owned when in fact 3,107 shares of the Issuer's common stock were owned, net of taxes withheld. As a result of this administrative error, the number of shares beneficially owned by the reporting person following the corrected transaction reflects a reduction in the number of shares reported as beneficially owned by the reporting person by 1,556 shares reflecting share withheld for the payment of taxes.
Footnote F3
The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.
Footnote F4
The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.